Biopharmaceutical Stocks
Entities in this sector focus on the discovery, development, and commercialization of complex therapeutic modalities, ranging from genomic editing and small molecule oncology to specialized diagnostic infrastructure. Revenue models are characterized by high research and development intensity, long clinical trial cycles, and significant binary risk associated with regulatory approval pathways.
As of Oct 23, 2026, Biopharmaceutical has 556 US-listed companies worth $3.6T combined. The median member moved +1.3% over the past week; GMAB led among the 25 largest at +18.4% and MRNA trailed at -8.2%.
Companies in Biopharmaceutical
- ABBV – AbbVie Inc, $505B
- MRK – Merck & Company Inc, $363B
- NVS – Novartis AG ADR, $287B
- AZN – AstraZeneca PLC, $266B
- GILD – Gilead Sciences Inc, $193B
- NVO – Novo Nordisk A/S, $172B
- PFE – Pfizer Inc, $171B
- BMY – Bristol-Myers Squibb Company, $129B
- GSK – GlaxoSmithKline PLC ADR, $103B
- SNY – Sanofi ADR, $99.7B
- REGN – Regeneron Pharmaceuticals Inc, $82.9B
- MRNA – Moderna Inc, $79.9B
- TAK – Takeda Pharmaceutical Co Ltd ADR, $64.7B
- ARGX – argenx NV ADR, $54.9B
- BDX – Becton Dickinson and Company, $54.6B
- TEVA – Teva Pharma Industries Ltd ADR, $46B
- ONC – BeiGene, Ltd., $43B
- RVMD – Revolution Medicines Inc, $40.2B
- RPRX – Royalty Pharma Plc, $36.8B
- ALNY – Alnylam Pharmaceuticals Inc, $30B
- ROIV – Roivant Sciences Ltd, $27.1B
- GMAB – Genmab AS, $26.9B
- INCY – Incyte Corporation, $23.7B
- BNTX – BioNTech SE, $22.9B
- INSM – Insmed Inc, $20.4B
- CRL – Charles River Laboratories, $16.6B
- ASND – Ascendis Pharma AS, $16B
- NBIX – Neurocrine Biosciences Inc, $14.6B
- HALO – Halozyme Therapeutics Inc, $14.1B
- JAZZ – Jazz Pharmaceuticals PLC, $13.9B
- BBIO – BridgeBio Pharma Inc, $13.4B
- SMMT – Summit Therapeutics PLC, $12.3B
- CORT – Corcept Therapeutics Incorporated, $11.6B
- TECH – Bio-Techne Corp, $11.4B
- RGEN – Repligen Corporation, $11.3B
- BMRN – Biomarin Pharmaceutical Inc, $10.8B
- GKOS – Glaukos Corp, $10.4B
- MDGL – Madrigal Pharmaceuticals Inc, $10B
- KRYS – Krystal Biotech Inc, $9.6B
- KYMR – Kymera Therapeutics Inc, $9.3B
- PTGX – Protagonist Therapeutics Inc, $9B
- IBRX – Immunitybio Inc, $8.8B
- CYTK – Cytokinetics Inc, $8.5B
- ARWR – Arrowhead Pharmaceuticals Inc, $8.2B
- TGTX – TG Therapeutics Inc, $8.1B
- ABVX – Abivax SA American Depositary Shares, $7.7B
- AXSM – Axsome Therapeutics Inc, $7.6B
- ALKS – Alkermes Plc, $7.4B
- IONS – Ionis Pharmaceuticals Inc, $7.3B
- PRAX – Praxis Precision Medicines Inc, $7.2B
- AMRX – Amneal Pharmaceuticals, Inc. Class A Common Stock, $7.1B
- IOVA – Iovance Biotherapeutics Inc, $6.4B
- KNSA – Kiniksa Pharmaceuticals Ltd, $6.3B
- RYTM – Rhythm Pharmaceuticals Inc, $6.3B
- LGND – Ligand Pharmaceuticals Incorporated, $6.1B
- IMVT – Immunovant Inc, $5.9B
- MANE – Veradermics, Incorporated, $5.8B
- STVN – Stevanato Group SpA, $5.5B
- KOD – Kodiak Sciences Inc, $5.4B
- MIRM – Mirum Pharmaceuticals Inc, $5.3B
- CGON – CG Oncology, Inc. Common stock, $5.3B
- PTCT – PTC Therapeutics Inc, $5.3B
- ORKA – Oruka Therapeutics, Inc., $5.2B
- GRFS – Grifols SA ADR, $5.2B
- SRRK – Scholar Rock Holding Corp, $5.1B
- ERAS – Erasca Inc, $5.1B
- TVTX – Travere Therapeutics Inc, $4.9B
- CRSP – Crispr Therapeutics AG, $4.8B
- TNGX – Tango Therapeutics Inc, $4.5B
- DFTX – Definium Therapeutics, Inc., $4.4B
- EWTX – Edgewise Therapeutics Inc, $4.3B
- DNTH – Dianthus Therapeutics Inc., $4.3B
- INDV – Indivior PLC Ordinary Shares, $4.2B
- ARQT – Arcutis Biotherapeutics Inc, $4B
- ABCL – Abcellera Biologics Inc, $3.8B
- TLX – Telix Pharmaceuticals Limited, $3.8B
- LEGN – Legend Biotech Corp, $3.7B
- AMLX – Amylyx Pharmaceuticals Inc, $3.6B
- LQDA – Liquidia Technologies Inc, $3.6B
- XENE – Xenon Pharmaceuticals Inc, $3.5B
- ACAD – ACADIA Pharmaceuticals Inc, $3.5B
- IDYA – Ideaya Biosciences Inc, $3.5B
- TARS – Tarsus Pharmaceuticals Inc, $3.3B
- PBLS – Parabilis Medicines, Inc. Common Stock, $3.1B
- IRON – Disc Medicine Inc., $3B
- DYN – Dyne Therapeutics Inc, $2.9B
- ELVN – Enliven Therapeutics Inc., $2.9B
- NRIX – Nurix Therapeutics Inc, $2.9B
- RCUS – Arcus Biosciences Inc, $2.8B
- ZLAB – Zai Lab Ltd, $2.7B
- VRDN – Viridian Therapeutics Inc, $2.5B
- BEAM – Beam Therapeutics Inc, $2.5B
- MBX – MBX Biosciences, Inc. Common Stock, $2.5B
- HCM – HUTCHMED DRC, $2.5B
- SUPN – Supernus Pharmaceuticals Inc, $2.4B
- MRVI – Maravai Lifesciences Holdings Inc, $2.4B
- ADMA – ADMA Biologics Inc, $2.4B
- NAMS – NewAmsterdam Pharma Company N.V. Ordinary Shares, $2.4B
- CLDX – Celldex Therapeutics Inc, $2.3B
- SLS – Sellas Life Sciences Group Inc, $2.3B
- PGEN – Precigen Inc, $2.3B
- VERA – Vera Therapeutics Inc, $2.2B
- AGIO – Agios Pharm, $2.2B
- AUPH – Aurinia Pharmaceuticals Inc, $2.2B
- AXGN – Axogen Inc, $2.2B
- VCEL – Vericel Corp Ord, $2.1B
- PHVS – Pharvaris BV, $2.1B
- IMNM – Immunome Inc, $2.1B
- XERS – Xeris Pharmaceuticals Inc, $2B
- BCRX – BioCryst Pharmaceuticals Inc, $2B
- ZYME – Zymeworks Inc. Common Stock, $1.9B
- RXRX – Recursion Pharmaceuticals Inc, $1.9B
- MLYS – Mineralys Therapeutics, Inc. Common Stock, $1.9B
- BRVE – Braveheart Bio, Inc. Common Stock, $1.9B
- BLFS – BioLife Solutions Inc, $1.9B
- NVAX – Novavax Inc, $1.9B
- XNCR – Xencor Inc, $1.9B
- GENB – Generate Biomedicines, Inc. Common Stock, $1.8B
- ZBIO – Zenas BioPharma, Inc. Common Stock, $1.8B
- SRPT – Sarepta Therapeutics Inc, $1.8B
- BHVN – Biohaven Ltd., $1.8B
- PVLA – Palvella Therapeutics, Inc, $1.7B
- MESO – Mesoblast Ltd, $1.7B
- NUVB – Nuvation Bio Inc, $1.7B
- KLRA – Kailera Therapeutics, Inc. Common Stock, $1.7B
- URGN – UroGen Pharma Ltd, $1.7B
- COAG – Hemab Therapeutics Holdings, Inc. Common Stock, $1.7B
- ANIP – ANI Pharmaceuticals Inc, $1.7B
- NBTX – Nanobiotix, $1.7B
- OCUL – Ocular Therapeutix Inc, $1.7B
- STOK – Stoke Therapeutics Inc, $1.7B
- GPCR – Structure Therapeutics Inc. American Depositary Shares, $1.6B
- NTLA – Intellia Therapeutics Inc, $1.6B
- QURE – Uniqure NV, $1.6B
- RARE – Ultragenyx, $1.6B
- KRSA – Korsana Biosciences, Inc., $1.5B
- ANAB – AnaptysBio Inc, $1.5B
- IMCR – Immunocore Holdings Ltd, $1.5B
- MAZE – Maze Therapeutics, Inc. Common Stock, $1.5B
- TYRA – Tyra Biosciences Inc, $1.5B
- INVA – Innoviva Inc, $1.5B
- ABSI – Absci Corp, $1.5B
- INBX – Inhibrx Biosciences, Inc., $1.4B
- AAPG – Ascentage Pharma Group International, $1.4B
- RAPP – Rapport Therapeutics, Inc. Common Stock, $1.3B
- GHRS – GH Research PLC, $1.3B
- REPL – Replimune Group Inc, $1.3B
- ORIC – Oric Pharmaceuticals Inc, $1.2B
- MNKD – MannKind Corp, $1.2B
- TRAX – First Tracks Biotherapeutics, $1.2B
- KARD – Kardigan, Inc. Common Stock, $1.2B
- LBRX – LB Pharmaceuticals Inc Common Stock, $1.2B
- VOR – Vor Biopharma Inc, $1.2B
- OMER – Omeros Corporation, $1.2B
- OPK – Opko Health Inc, $1.2B
- BCAX – Bicara Therapeutics Inc. Common Stock, $1.2B
- DMRA – Damora Therapeutics, Inc., $1.2B
- JANX – Janux Therapeutics Inc, $1.1B
- LTGO – Latigo Biotherapeutics, Inc. Common Stock, $1.1B
- IMTX – Immatics NV, $1B
- SVRA – Savara Inc, $1B
- PCRX – Pacira BioSciences, Inc., $1B
- ANL – Adlai Nortye Ltd. American Depositary Shares, $999M
- SPTX – Seaport Therapeutics, Inc. Common Stock, $986M
- CGEM – Cullinan Oncology LLC, $961M
- ANRO – Alto Neuroscience, Inc., $956M
- KURA – Kura Oncology Inc, $944M
- AKTS – Aktis Oncology, Inc. Common stock, $890M
- ALMS – Alumis Inc, $885M
- CRVS – Corvus Pharmaceuticals Inc, $876M
- ARDX – Ardelyx Inc, $842M
- GLUE – Monte Rosa Therapeutics Inc, $839M
- SANA – Sana Biotechnology Inc, $835M
- AVBP – ArriVent BioPharma, Inc. Common Stock, $821M
- IMMX – Immix Biopharma Inc, $803M
- SGP – SpyGlass Pharma, Inc., $792M
- LXRX – Lexicon Pharmaceuticals Inc, $783M
- VSTM – Verastem Inc, $781M
- APMD – Apnimed, Inc. Common Stock, $771M
- GERN – Geron Corporation, $771M
- IVA – Inventiva Sa, $770M
- OBX – Obsidian Therapeutics, Inc. Common Stock, $741M
- FTH – Faeth Therapeutics, Inc., $733M
- DSGN – Design Therapeutics Inc, $732M
- AVTX – Avalo Therapeutics Inc, $728M
- ANNX – Annexon Inc, $726M
- MLAB – Mesa Laboratories Inc, $722M
- GYRE – Gyre Therapeutics Inc., $717M
- NVCT – Nuvectis Pharma Inc, $716M
- CADL – Candel Therapeutics Inc, $709M
- PRME – Prime Medicine, Inc. Common Stock, $707M
- COLL – Collegium Pharmaceutical Inc, $701M
- PHAR – Pharming Group NV, $690M
- OLMA – Olema Pharmaceuticals Inc, $684M
- ZVRA – Zevra Therapeutics Inc., $676M
- MDXG – MiMedx Group Inc, $670M
- DBVT – DBV Technologies, $663M
- OABI – OmniAb Inc., $663M
- ABUS – Arbutus Biopharma Corp, $648M
- IRWD – Ironwood Pharmaceuticals Inc, $620M
Showing the 200 largest of 556 members by market cap.